Amarin Corp Plcuk (AMRN) Liabilities and Shareholders Equity (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported Liabilities and Shareholders Equity of $645.8 million for Q1 2026, down 1.52% year-over-year from $655.7 million in Q1 2025, and down 3.73% quarter-over-quarter from $670.8 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $645.8 million in Q1 2026.
- Liabilities and Shareholders Equity for Q1 2026 came in at $645.8 million, down 1.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.6 billion (down 8.48% YoY), and the FY2025 annual result was $670.8 million, down 2.13% from the prior year.
- Liabilities and Shareholders Equity eased to $645.8 million in Q1 2026 per AMRN's latest filing, from $670.8 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $973.7 million in Q1 2022 and troughed at $645.8 million in Q1 2026.
- A 5-year average of $791.8 million and a median of $799.9 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2024 and 2026: Liabilities and Shareholders Equity dropped 17.6% in 2024, then retreated 1.52% in 2026.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $886.2 million in 2022, then decreased by 6.15% to $831.7 million in 2023, then retreated by 17.6% to $685.3 million in 2024, then decreased by 2.13% to $670.8 million in 2025, then retreated by 3.73% to $645.8 million in 2026.
- Business Quant data shows AMRN's Liabilities and Shareholders Equity at $645.8 million in Q1 2026, $670.8 million in Q4 2025, and $659.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 84.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 116.58 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 200.89 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 136.46 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 128.69 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 92.50 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 56.28 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 208.00 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 86.48 Bn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn | 645.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 645.76 Mn |
| Dec 31, 2025 | 670.78 Mn |
| Sep 30, 2025 | 659.81 Mn |
| Jun 30, 2025 | 670.13 Mn |
| Mar 31, 2025 | 655.70 Mn |
| Dec 31, 2024 | 685.35 Mn |
| Sep 30, 2024 | 750.62 Mn |
| Jun 30, 2024 | 799.90 Mn |
| Mar 31, 2024 | 790.01 Mn |
| Dec 31, 2023 | 831.68 Mn |
| Sep 30, 2023 | 839.03 Mn |
| Jun 30, 2023 | 860.02 Mn |
| Mar 31, 2023 | 860.19 Mn |
| Dec 31, 2022 | 886.18 Mn |
| Sep 30, 2022 | 908.30 Mn |
| Jun 30, 2022 | 973.24 Mn |
| Mar 31, 2022 | 973.71 Mn |
| Dec 31, 2021 | 1.07 Bn |
| Sep 30, 2021 | 1.04 Bn |
| Jun 30, 2021 | 1.04 Bn |